{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:45:19Z","timestamp":1792107919313,"version":"4.4.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012684","name":"Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston","doi-asserted-by":"publisher","award":["1UM1TR004906-01"],"award-info":[{"award-number":["1UM1TR004906-01"]}],"id":[{"id":"10.13039\/100012684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00467-026-07293-8","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:33:41Z","timestamp":1777088021000},"page":"4291-4303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-obesity medications in children and adolescents: blood pressure and chronic kidney disease implications"],"prefix":"10.1007","volume":"41","author":[{"given":"Margaret A.","family":"Clement","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1552-9025","authenticated-orcid":false,"given":"Joyce P.","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"7293_CR1","unstructured":"Centers for Disease Control and Prevention (2024) Adult BMI categories. U.S. Department of Health and Human Services. https:\/\/www.cdc.gov\/bmi\/adult-calculator\/bmi-categories.html.\u00a0Accessed 21 Jan 2026"},{"key":"7293_CR2","unstructured":"Centers for Disease Control and Prevention (2024) Child and teen BMI categories. U.S. Department of Health and Human Services. https:\/\/www.cdc.gov\/bmi\/child-teen-calculator\/bmi-categories.html. Accessed 21 Jan 2026"},{"key":"7293_CR3","first-page":"1","volume":"59","author":"LM Grummer-Strawn","year":"2010","unstructured":"Grummer-Strawn LM, Reinold C, Krebs NF (2010) Use of World Health Organization and CDC growth charts for children aged 0\u201359 months in the United States. MMWR Recomm Rep 59:1\u201315","journal-title":"MMWR Recomm Rep"},{"key":"7293_CR4","unstructured":"World Health Organization (2026) Weight for length\/height charts. https:\/\/www.who.int\/tools\/child-growth-standards\/standards\/weight-for-length-height.\u00a0Accessed 21 Jan 2026 \u00a0"},{"key":"7293_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12887-017-0891-z","volume":"17","author":"C Vanderwall","year":"2017","unstructured":"Vanderwall C, Randall Clark R, Eickhoff J, Carrel AL (2017) BMI is a poor predictor of adiposity in young overweight and obese children. BMC Pediatr 17:135. https:\/\/doi.org\/10.1186\/s12887-017-0891-z","journal-title":"BMC Pediatr"},{"key":"7293_CR6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-1072","volume":"140","author":"DS Freedman","year":"2017","unstructured":"Freedman DS, Berenson GS (2017) Tracking of BMI. Pediatrics 140:e20171072. https:\/\/doi.org\/10.1542\/peds.2017-1072","journal-title":"Pediatrics"},{"key":"7293_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA et al (2025) Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol 13:221\u2013262. https:\/\/doi.org\/10.1016\/S2213-8587(24)00316-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7293_CR8","doi-asserted-by":"publisher","unstructured":"Stierman B, Afful J, Carroll MD, Chen TC, Davy O, Fink S et al (2021) National Health and Nutrition Examination Survey 2017-March 2020 prepandemic data files-development of files and prevalence estimates for selected health outcomes. Natl Health Stat Report. https:\/\/doi.org\/10.15620\/cdc:106273","DOI":"10.15620\/cdc:106273"},{"key":"7293_CR9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1001\/jama.2020.14590","volume":"324","author":"CL Ogden","year":"2020","unstructured":"Ogden CL, Fryar CD, Martin CB, Freedman DS, Carroll MD, Gu Q, Hales CM (2020) Trends in obesity prevalence by race and Hispanic origin-1999-2000 to 2017\u20132018. JAMA 324:1208\u20131210. https:\/\/doi.org\/10.1001\/jama.2020.14590","journal-title":"JAMA"},{"key":"7293_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3945\/an.110.000083","volume":"2","author":"Y Wang","year":"2011","unstructured":"Wang Y (2011) Disparities in pediatric obesity in the United States. Adv Nutr 2:23\u201331. https:\/\/doi.org\/10.3945\/an.110.000083","journal-title":"Adv Nutr"},{"key":"7293_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0140-6736(25)00397-6","volume":"405","author":"GBD 2021 Adolescent Collaborators","year":"2025","unstructured":"GBD 2021 Adolescent Collaborators (2025) Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021. Lancet 405:785\u2013812. https:\/\/doi.org\/10.1016\/S0140-6736(25)00397-6","journal-title":"Lancet"},{"key":"7293_CR12","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS et al (2023) Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148:1606\u20131635. https:\/\/doi.org\/10.1161\/CIR.0000000000001184","journal-title":"Circulation"},{"key":"7293_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1001\/jama.2024.11146","volume":"332","author":"WK Nicholson","year":"2024","unstructured":"US Preventive Services Task Force, Nicholson WK, Silverstein M, Wong JB, Chelmow D, Coker TR et al (2024) Interventions for high body mass index in children and adolescents: US Preventive Services Task Force recommendation statement. JAMA 332:226\u2013232. https:\/\/doi.org\/10.1001\/jama.2024.11146","journal-title":"JAMA"},{"key":"7293_CR14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060640","volume":"151","author":"SE Hampl","year":"2023","unstructured":"Hampl SE, Hassink SG, Skinner AC, Armstrong SC, Barlow SE, Bolling CF et al (2023) Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics 151:e2022060640. https:\/\/doi.org\/10.1542\/peds.2022-060640","journal-title":"Pediatrics"},{"key":"7293_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1542\/peds.2010-0697","volume":"127","author":"M Savoye","year":"2011","unstructured":"Savoye M, Nowicka P, Shaw M, Yu S, Dziura J, Chavent G et al (2011) Long-term results of an obesity program in an ethnically diverse pediatric population. Pediatrics 127:402\u2013410. https:\/\/doi.org\/10.1542\/peds.2010-0697","journal-title":"Pediatrics"},{"key":"7293_CR16","unstructured":"Children's Hospital Association (2014) 2013 survey findings on children's hospitals obesity services. Overland Park, KS"},{"key":"7293_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1210\/jc.2016-2573","volume":"102","author":"DM Styne","year":"2017","unstructured":"Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, Yanovski JA (2017) Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 102:709\u2013757. https:\/\/doi.org\/10.1210\/jc.2016-2573","journal-title":"J Clin Endocrinol Metab"},{"key":"7293_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-084760","volume":"390","author":"LL Hagenaars","year":"2025","unstructured":"Hagenaars LL, Bero LA, Van Der Voorn B, Schmidt LA (2025) Caution is prescribed for American Academy of Paediatrics\u2019 guidelines on weight loss medications for childhood obesity. BMJ 390:e084760. https:\/\/doi.org\/10.1136\/bmj-2025-084760","journal-title":"BMJ"},{"key":"7293_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S2213-8587(22)00047-X","volume":"10","author":"H Jebeile","year":"2022","unstructured":"Jebeile H, Kelly AS, O\u2019malley G, Baur LA (2022) Obesity in children and adolescents: epidemiology, causes, assessment, and management. Lancet Diabetes Endocrinol 10:351\u2013365. https:\/\/doi.org\/10.1016\/S2213-8587(22)00047-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7293_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41366-024-01465-y","volume":"49","author":"CK Fox","year":"2025","unstructured":"Fox CK, Kelly AS, Reilly JL, Theis-Mahon N, Raatz SJ (2025) Current and future state of pharmacological management of pediatric obesity. Int J Obes 49:388\u2013396. https:\/\/doi.org\/10.1038\/s41366-024-01465-y","journal-title":"Int J Obes"},{"key":"7293_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S2213-8587(24)00312-7","volume":"13","author":"CL Roth","year":"2025","unstructured":"Roth CL (2025) Setmelanotide for the treatment of severe early-childhood genetic obesity. Lancet Diabetes Endocrinol 13:3\u20134. https:\/\/doi.org\/10.1016\/S2213-8587(24)00312-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7293_CR22","doi-asserted-by":"publisher","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","volume":"267","author":"J Eng","year":"1992","unstructured":"Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402\u20137405","journal-title":"J Biol Chem"},{"key":"7293_CR23","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K et al (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 24:1553\u20131564. https:\/\/doi.org\/10.1111\/dom.14725","journal-title":"Diabetes Obes Metab"},{"key":"7293_CR24","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M (2023) Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 330:1795\u20131797. https:\/\/doi.org\/10.1001\/jama.2023.19574","journal-title":"JAMA"},{"key":"7293_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, Yang N, Huang J, Li Y et al (2022) Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 182:513\u2013519. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0338","journal-title":"JAMA Intern Med"},{"key":"7293_CR26","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389:2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"7293_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/thy.2024.0387","volume":"35","author":"SM Baxter","year":"2025","unstructured":"Baxter SM, Lund LC, Andersen JH, Brix TH, Hegedus L, Hsieh MH et al (2025) Glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study. Thyroid 35:69\u201378. https:\/\/doi.org\/10.1089\/thy.2024.0387","journal-title":"Thyroid"},{"key":"7293_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/jamaoto.2024.4852","volume":"151","author":"JP Brito","year":"2025","unstructured":"Brito JP, Herrin J, Swarna KS, Singh Ospina NM, Montori VM, Toro-Tobon D et al (2025) GLP-1RA use and thyroid cancer risk. JAMA Otolaryngol Head Neck Surg 151:243\u2013252. https:\/\/doi.org\/10.1001\/jamaoto.2024.4852","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"7293_CR29","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber D, Barrett T, Barrientos-P\u00e9rez M, Gies I, Hesse D, Jeppesen OK et al (2022) Once-weekly semaglutide in adolescents with obesity. N Engl J Med 387:2245\u20132257. https:\/\/doi.org\/10.1056\/NEJMoa2208601","journal-title":"N Engl J Med"},{"key":"7293_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/children10020208","volume":"10","author":"A Cornejo-Estrada","year":"2023","unstructured":"Cornejo-Estrada A, Nieto-Rodr\u00edguez C, Le\u00f3n-Figueroa DA, Moreno-Ramos E, Cabanillas-Ramirez C, Barboza JJ (2023) Efficacy of liraglutide in obesity in children and adolescents: systematic review and meta-analysis of randomized controlled trials. Children 10:208. https:\/\/doi.org\/10.3390\/children10020208","journal-title":"Children"},{"key":"7293_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12495","volume":"14","author":"LD Mastrandrea","year":"2019","unstructured":"Mastrandrea LD, Witten L, Carlsson Petri KC, Hale PM, Hedman HK, Riesenberg RA (2019) Liraglutide effects in a paediatric (7\u201311 y) population with obesity: a randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Pediatr Obes 14:e12495. https:\/\/doi.org\/10.1111\/ijpo.12495","journal-title":"Pediatr Obes"},{"key":"7293_CR32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jpeds.2016.10.076","volume":"181","author":"T Danne","year":"2017","unstructured":"Danne T, Biester T, Kapitzke K, Jacobsen SH, Jacobsen LV, Petri KCC et al (2017) Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12\u201317 years. J Pediatr 181:146\u2013153. https:\/\/doi.org\/10.1016\/j.jpeds.2016.10.076","journal-title":"J Pediatr"},{"key":"7293_CR33","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C et al (2020) A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med 382:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1916038","journal-title":"N Engl J Med"},{"key":"7293_CR34","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1001\/jama.2024.7112","volume":"331","author":"JM Lee","year":"2024","unstructured":"Lee JM, Sharifi M, Oshman L, Griauzde DH, Chua KP (2024) Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020\u20132023. JAMA 331:2041\u20132043. https:\/\/doi.org\/10.1001\/jama.2024.7112","journal-title":"JAMA"},{"key":"7293_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019neil PM, Rosenstock J, Sorrig R et al (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 327:138\u2013150. https:\/\/doi.org\/10.1001\/jama.2021.23619","journal-title":"JAMA"},{"key":"7293_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, Le Roux CW, Ho W, Falcon BL, Gomez Valderas E et al (2025) Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 393:26\u201336. https:\/\/doi.org\/10.1056\/NEJMoa2416394","journal-title":"N Engl J Med"},{"key":"7293_CR37","unstructured":"Clinicaltrials.gov (2026) A study of tirzepatide in adolescents with obesity and weight-related comorbidities (SURMOUNT-adolescents-2). NIH National Library of Medicine.\u00a0https:\/\/clinicaltrials.gov\/study\/NCT06439277. Accessed 4 Feb 2026"},{"key":"7293_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/biom15060796","volume":"15","author":"V Katsi","year":"2025","unstructured":"Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K (2025) Retatrutide-a game changer in obesity pharmacotherapy. Biomolecules 15:796. https:\/\/doi.org\/10.3390\/biom15060796","journal-title":"Biomolecules"},{"key":"7293_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2024-017177","volume":"9","author":"Y Jeyakumar","year":"2024","unstructured":"Jeyakumar Y, Richardson L, Sarma S, Retnakaran R, Kramer CK (2024) Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps. BMJ Glob Health 9:e017177. https:\/\/doi.org\/10.1136\/bmjgh-2024-017177","journal-title":"BMJ Glob Health"},{"key":"7293_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-023-01467-3","volume":"5","author":"L Galassi","year":"2023","unstructured":"Galassi L, Facchinetti F (2023) Carbonation and sweet taste dysgeusia with topiramate therapy for migraine prevention treatment: a case report. SN Compr Clin Med 5:123. https:\/\/doi.org\/10.1007\/s42399-023-01467-3","journal-title":"SN Compr Clin Med"},{"key":"7293_CR41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/AHMT.S383454","volume":"14","author":"A Kim","year":"2023","unstructured":"Kim A, Nguyen J, Babaei M, Geller DH, Vidmar AP (2023) A narrative review: phentermine and topiramate for the treatment of pediatric obesity. Adolesc Health Med Ther 14:125\u2013140. https:\/\/doi.org\/10.2147\/AHMT.S383454","journal-title":"Adolesc Health Med Ther"},{"key":"7293_CR42","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","volume":"403","author":"Q Shi","year":"2024","unstructured":"Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J et al (2024) Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 403:e21\u2013e31. https:\/\/doi.org\/10.1016\/S0140-6736(24)00351-9","journal-title":"Lancet"},{"key":"7293_CR43","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200014","author":"AS Kelly","year":"2022","unstructured":"Kelly AS, Bensignor MO, Hsia DS, Shoemaker AH, Shih W, Peterson C, Varghese ST (2022) Phentermine\/topiramate for the treatment of adolescent obesity. NEJM Evid. https:\/\/doi.org\/10.1056\/evidoa2200014","journal-title":"NEJM Evid"},{"key":"7293_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107657","volume":"115","author":"YL Dang","year":"2021","unstructured":"Dang YL, Foster E, Lloyd M, Rayner G, Rychkova M, Ali R et al (2021) Adverse events related to antiepileptic drugs. Epilepsy Behav 115:107657. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107657","journal-title":"Epilepsy Behav"},{"key":"7293_CR45","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ogla.2024.04.006","volume":"7","author":"OM Aftab","year":"2024","unstructured":"Aftab OM, Khan H, Khouri AS (2024) Blind spots in therapy: unveiling drug-induced angle-closure glaucoma through a national analysis. Ophthalmol Glaucoma 7:485\u2013490. https:\/\/doi.org\/10.1016\/j.ogla.2024.04.006","journal-title":"Ophthalmol Glaucoma"},{"key":"7293_CR46","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","volume":"293","author":"JP Chanoine","year":"2005","unstructured":"Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J (2005) Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 293:2873\u20132883. https:\/\/doi.org\/10.1001\/jama.293.23.2873","journal-title":"JAMA"},{"key":"7293_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-218623","volume":"2017","author":"LR Solomon","year":"2017","unstructured":"Solomon LR, Nixon AC, Ogden L, Nair B (2017) Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease. BMJ Case Rep 2017:bcr-2016-218623. https:\/\/doi.org\/10.1136\/bcr-2016-218623","journal-title":"BMJ Case Rep"},{"key":"7293_CR48","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/archinternmed.2011.103","volume":"171","author":"MA Weir","year":"2011","unstructured":"Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG (2011) Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med 171:703\u2013704. https:\/\/doi.org\/10.1001\/archinternmed.2011.103","journal-title":"Arch Intern Med"},{"key":"7293_CR49","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/adc.41.217.309","volume":"41","author":"J Lorber","year":"1966","unstructured":"Lorber J (1966) Obesity in childhood. A controlled trial of anorectic drugs. Arch Dis Child 41:309\u2013312. https:\/\/doi.org\/10.1136\/adc.41.217.309","journal-title":"Arch Dis Child"},{"key":"7293_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1347047","volume":"15","author":"M Cheng","year":"2024","unstructured":"Cheng M, Ren L, Jia X, Wang J, Cong B (2024) Understanding the action mechanisms of metformin in the gastrointestinal tract. Front Pharmacol 15:1347047. https:\/\/doi.org\/10.3389\/fphar.2024.1347047","journal-title":"Front Pharmacol"},{"key":"7293_CR51","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1056\/NEJM199508313330902","volume":"333","author":"RA Defronzo","year":"1995","unstructured":"Defronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541\u2013549. https:\/\/doi.org\/10.1056\/NEJM199508313330902","journal-title":"N Engl J Med"},{"key":"7293_CR52","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1056\/NEJM199508313330903","volume":"333","author":"M Stumvoll","year":"1995","unstructured":"Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE (1995) Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550\u2013554. https:\/\/doi.org\/10.1056\/NEJM199508313330903","journal-title":"N Engl J Med"},{"key":"7293_CR53","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577\u20131589. https:\/\/doi.org\/10.1056\/NEJMoa0806470","journal-title":"N Engl J Med"},{"key":"7293_CR54","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2337\/dc11-1299","volume":"35","author":"Diabetes Prevention Program Research Group","year":"2012","unstructured":"Diabetes Prevention Program Research Group (2012) Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program outcomes study. Diabetes Care 35:731\u2013737. https:\/\/doi.org\/10.2337\/dc11-1299","journal-title":"Diabetes Care"},{"key":"7293_CR55","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-1610","volume":"147","author":"R Masarwa","year":"2021","unstructured":"Masarwa R, Brunetti VC, Aloe S, Henderson M, Platt RW, Filion KB (2021) Efficacy and safety of metformin for obesity: a systematic review. Pediatrics 147:e20201610. https:\/\/doi.org\/10.1542\/peds.2020-1610","journal-title":"Pediatrics"},{"key":"7293_CR56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/2045125316629071","volume":"6","author":"K Patel","year":"2016","unstructured":"Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK (2016) Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol 6:99\u2013144. https:\/\/doi.org\/10.1177\/2045125316629071","journal-title":"Ther Adv Psychopharmacol"},{"key":"7293_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01319-7","volume":"16","author":"Y Liu","year":"2024","unstructured":"Liu Y, Han F, Xia Z, Sun P, Rohani P, Amirthalingam P, Sohouli MH (2024) The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials. Diabetol Metab Syndr 16:93. https:\/\/doi.org\/10.1186\/s13098-024-01319-7","journal-title":"Diabetol Metab Syndr"},{"key":"7293_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/oby.21360","volume":"24","author":"L Floden","year":"2016","unstructured":"Floden L, Taren DL, Muramoto ML, Leischow SJ (2016) BMI changes in adolescents treated with bupropion SR for smoking cessation. Obesity 24:26\u201329. https:\/\/doi.org\/10.1002\/oby.21360","journal-title":"Obesity"},{"key":"7293_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00290","volume":"11","author":"KS Czepiel","year":"2020","unstructured":"Czepiel KS, Perez NP, Campoverde Reyes KJ, Sabharwal S, Stanford FC (2020) Pharmacotherapy for the treatment of overweight and obesity in children, adolescents, and young adults in a large health system in the US. Front Endocrinol 11:290. https:\/\/doi.org\/10.3389\/fendo.2020.00290","journal-title":"Front Endocrinol"},{"key":"7293_CR60","first-page":"164","volume":"41","author":"MM Sherman","year":"2016","unstructured":"Sherman MM, Ungureanu S, Rey JA (2016) Naltrexone\/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults. PT 41:164\u2013172","journal-title":"PT"},{"key":"7293_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1649543","volume":"16","author":"A Pascarella","year":"2025","unstructured":"Pascarella A, Marsico O, Abelardo D, Cutelle R, Bulgari A, Mummolo C et al (2025) Epilepsy and migraine: a diagnostic and therapeutic challenge. Front Pharmacol 16:1649543. https:\/\/doi.org\/10.3389\/fphar.2025.1649543","journal-title":"Front Pharmacol"},{"key":"7293_CR62","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/0091217415621266","volume":"51","author":"M Shapiro","year":"2016","unstructured":"Shapiro M, Reid A, Olsen B, Taasan M, Mcnamara J, Nguyen M (2016) Topiramate, zonisamide and weight loss in children and adolescents prescribed psychiatric medications: a medical record review. Int J Psychiatry Med 51:56\u201368. https:\/\/doi.org\/10.1177\/0091217415621266","journal-title":"Int J Psychiatry Med"},{"key":"7293_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-4-5","volume":"4","author":"D Arnone","year":"2005","unstructured":"Arnone D (2005) Review of the use of topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 4:5. https:\/\/doi.org\/10.1186\/1744-859X-4-5","journal-title":"Ann Gen Psychiatry"},{"key":"7293_CR64","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/s0920-1211(03)00028-7","volume":"53","author":"Y Mikaeloff","year":"2003","unstructured":"Mikaeloff Y, De Saint-Martin A, Mancini J, Peudenier S, Pedespan JM, Vallee L et al (2003) Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 53:225\u2013232. https:\/\/doi.org\/10.1016\/s0920-1211(03)00028-7","journal-title":"Epilepsy Res"},{"key":"7293_CR65","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/j.1526-4610.2005.00262.x","volume":"45","author":"P Winner","year":"2005","unstructured":"Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J, Topiramate Pediatric Migraine Study Investigators (2005) Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 45:1304\u20131312. https:\/\/doi.org\/10.1111\/j.1526-4610.2005.00262.x","journal-title":"Headache"},{"key":"7293_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0597-0","volume":"9","author":"A Consoli","year":"2019","unstructured":"Consoli A, Cabal Berthoumieu S, Raffin M, Thuilleaux D, Poitou C, Coupaye M et al (2019) Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study. Transl Psychiatry 9:274. https:\/\/doi.org\/10.1038\/s41398-019-0597-0","journal-title":"Transl Psychiatry"},{"key":"7293_CR67","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1002\/oby.21633","volume":"24","author":"CK Fox","year":"2016","unstructured":"Fox CK, Kaizer AM, Rudser KD, Nathan BM, Gross AC, Sunni M et al (2016) Meal replacements followed by topiramate for the treatment of adolescent severe obesity: a pilot randomized controlled trial. Obesity 24:2553\u20132561. https:\/\/doi.org\/10.1002\/oby.21633","journal-title":"Obesity"},{"key":"7293_CR68","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-1662","volume":"137","author":"ED Parker","year":"2016","unstructured":"Parker ED, Sinaiko AR, Kharbanda EO, Margolis KL, Daley MF, Trower NK et al (2016) Change in weight status and development of hypertension. Pediatrics 137:e20151662. https:\/\/doi.org\/10.1542\/peds.2015-1662","journal-title":"Pediatrics"},{"key":"7293_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s40885-024-00278-5","volume":"30","author":"SI Jeong","year":"2024","unstructured":"Jeong SI, Kim SH (2024) Obesity and hypertension in children and adolescents. Clin Hypertens 30:23. https:\/\/doi.org\/10.1186\/s40885-024-00278-5","journal-title":"Clin Hypertens"},{"key":"7293_CR70","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1161\/01.hyp.36.4.531","volume":"36","author":"C Weyer","year":"2000","unstructured":"Weyer C, Pratley RE, Snitker S, Spraul M, Ravussin E, Tataranni PA (2000) Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 36:531\u2013537. https:\/\/doi.org\/10.1161\/01.hyp.36.4.531","journal-title":"Hypertension"},{"key":"7293_CR71","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/s41366-019-0384-2","volume":"43","author":"E Hagman","year":"2019","unstructured":"Hagman E, Danielsson P, Elimam A, Marcus C (2019) The effect of weight loss and weight gain on blood pressure in children and adolescents with obesity. Int J Obes 43:1988\u20131994. https:\/\/doi.org\/10.1038\/s41366-019-0384-2","journal-title":"Int J Obes"},{"key":"7293_CR72","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"7293_CR73","doi-asserted-by":"publisher","unstructured":"De Lemos JA, Linetzky B, Le Roux CW, Laffin LJ, Vongpatanasin W, Fan L et al (2024) Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u226527 kg\/m2: SURMOUNT-1 ambulatory blood pressure monitoring substudy. Hypertension 81:e41. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.123.22022","DOI":"10.1161\/HYPERTENSIONAHA.123.22022"},{"key":"7293_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103464","volume":"88","author":"J Chu","year":"2025","unstructured":"Chu J, Zhang H, Wu Y, Huang Y, Zhu T, Zhou Z, Wang H (2025) Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis. EClinicalMedicine 88:103464. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103464","journal-title":"EClinicalMedicine"},{"key":"7293_CR75","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jamapediatrics.2025.3243","volume":"179","author":"P Kotecha","year":"2025","unstructured":"Kotecha P, Huang W, Yeh YY, Narvaez VM, Adirika D, Tang H et al (2025) Efficacy and safety of GLP-1 RAs in children and adolescents with obesity or type 2 diabetes: a systematic review and meta-analysis. JAMA Pediatr 179:1308\u20131317. https:\/\/doi.org\/10.1001\/jamapediatrics.2025.3243","journal-title":"JAMA Pediatr"},{"key":"7293_CR76","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1038\/s41440-025-02418-2","volume":"48","author":"M Tanaka","year":"2025","unstructured":"Tanaka M, Itoh H (2025) Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight. Hypertens Res 48:3159\u20133171. https:\/\/doi.org\/10.1038\/s41440-025-02418-2","journal-title":"Hypertens Res"},{"key":"7293_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237025","volume":"13","author":"G Forcina","year":"2024","unstructured":"Forcina G, Luciano M, Frattolillo V, Mori S, Monaco N, Guarino S et al (2024) Kidney damage in pediatric obesity: insights from an emerging perspective. J Clin Med 13:7025. https:\/\/doi.org\/10.3390\/jcm13237025","journal-title":"J Clin Med"},{"key":"7293_CR78","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1053\/j.ajkd.2022.06.007","volume":"80","author":"AN Friedman","year":"2022","unstructured":"Friedman AN, Schauer PR, Beddhu S, Kramer H, Le Roux CW, Purnell JQ et al (2022) Obstacles and opportunities in managing coexisting obesity and CKD: report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society. Am J Kidney Dis 80:783\u2013793. https:\/\/doi.org\/10.1053\/j.ajkd.2022.06.007","journal-title":"Am J Kidney Dis"},{"key":"7293_CR79","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrneph.2016.191","volume":"13","author":"NO Camara","year":"2017","unstructured":"Camara NO, Iseki K, Kramer H, Liu ZH, Sharma K (2017) Kidney disease and obesity: epidemiology, mechanisms and treatment. Nat Rev Nephrol 13:181\u2013190. https:\/\/doi.org\/10.1038\/nrneph.2016.191","journal-title":"Nat Rev Nephrol"},{"key":"7293_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00467-021-05148-y","volume":"37","author":"S Stabouli","year":"2022","unstructured":"Stabouli S, Polderman N, Nelms CL, Paglialonga F, Oosterveld MJS, Greenbaum LA et al (2022) Assessment and management of obesity and metabolic syndrome in children with CKD stages 2\u20135 on dialysis and after kidney transplantation-clinical practice recommendations from the Pediatric Renal Nutrition Taskforce. Pediatr Nephrol 37:1\u201320. https:\/\/doi.org\/10.1007\/s00467-021-05148-y","journal-title":"Pediatr Nephrol"},{"key":"7293_CR81","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G et al (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391:109\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"key":"7293_CR82","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE et al (2024) Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med 30:2058\u20132066. https:\/\/doi.org\/10.1038\/s41591-024-03015-5","journal-title":"Nat Med"},{"key":"7293_CR83","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S et al (2017) Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377:839\u2013848. https:\/\/doi.org\/10.1056\/NEJMoa1616011","journal-title":"N Engl J Med"},{"key":"7293_CR84","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"7293_CR85","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194749","volume":"135","author":"ME Cooper","year":"2025","unstructured":"Cooper ME, Van Raalte DH (2025) GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. J Clin Invest 135:e194749. https:\/\/doi.org\/10.1172\/JCI194749","journal-title":"J Clin Invest"},{"key":"7293_CR86","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105:S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"7293_CR87","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1506699","volume":"374","author":"TH Inge","year":"2016","unstructured":"Inge TH, Courcoulas AP, Jenkins TM, Michalsky MP, Helmrath MA, Brandt ML et al (2016) Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med 374:113\u2013123. https:\/\/doi.org\/10.1056\/NEJMoa1506699","journal-title":"N Engl J Med"},{"key":"7293_CR88","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1089\/chi.2022.0062","volume":"19","author":"C Berman","year":"2023","unstructured":"Berman C, Naguib M, Hegedus E, Vidmar AP (2023) Topiramate for weight management in children with severe obesity. Child Obes 19:219\u2013225. https:\/\/doi.org\/10.1089\/chi.2022.0062","journal-title":"Child Obes"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07293-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07293-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07293-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:54:31Z","timestamp":1792104871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07293-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":88,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["7293"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07293-8","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or proprietary interests in any material discussed in this article.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}